Paper Details

  1. Home
  2. Paper Details

Simvastatin as a treatment for pulmonary hypertension trial.

Author: , AliOmar, BradlowWilliam, GhofraniHossein A, GibbsJ Simon R, HowardLuke, MohiaddinRaad H, NihoyannopoulosPetros, RhodesChristopher J, TaegtmeyerAnne, WhartonJohn, WilkinsMartin R

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Simvastatin, added to conventional therapy, showed a small and transient early reduction in right ventricular (RV) mass and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with pulmonary arterial hypertension (PAH). While RV mass decreased by 5.2 g and NT-proBNP levels decreased by 75 fmol/ml in the simvastatin group after 6 months, these effects were not sustained over 12 months.
Paper Details　
Original Abstract of the Article :
RATIONALE: In animal models of pulmonary hypertension, simvastatin has been shown to reduce pulmonary artery pressure and induce regression of associated right ventricular (RV) hypertrophy. OBJECTIVES: To assess the therapeutic value of simvastatin in patients with pulmonary arterial hypertension (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874452/

データ提供：米国国立医学図書館（NLM）

Simvastatin: A Potential Treatment for Pulmonary Hypertension

Pulmonary hypertension, a serious condition characterized by high blood pressure in the arteries of the lungs, can significantly impact the heart and overall health. This study investigates the therapeutic potential of simvastatin, a statin medication commonly used to lower cholesterol, in treating pulmonary arterial hypertension (PAH).

Simvastatin in PAH: A New Oasis in the Desert of Treatment Options

The study, like a skilled explorer searching for a new route, investigates the potential benefits of simvastatin in treating PAH. While the findings suggest a transient reduction in right ventricular mass and NT-proBNP levels, further research is needed to confirm the long-term efficacy and safety of this approach.

A Glimpse of Hope: Simvastatin for Pulmonary Hypertension

The findings of this study, like a refreshing oasis in the desert of PAH treatment, offer a glimmer of hope for individuals seeking alternative treatment options. While more research is necessary, simvastatin may represent a promising avenue for exploring new therapies for this debilitating disease.

Dr.Camel's Conclusion

The quest for effective treatments for PAH is like a caravan journey across a vast and challenging desert. This study, like a beacon of hope, sheds light on the potential of simvastatin as a therapeutic option, offering a glimmer of optimism in the ongoing search for improved treatments for this debilitating disease.

Date :
  1. Date Completed 2010-06-09
  2. Date Revised 2021-10-28
Further Info :

Pubmed ID

20460548

DOI: Digital Object Identifier

PMC2874452

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.